Airbnb asks NYC to reconsider regulations on short-term rentals
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Wall St set for lower open as Middle East clashes revive rate-hike speculation
- The Warsh pivot markets didn't expect
- Oil rises over 2% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
- GameStop posts higher income despite revenue drop in Q2 2026
- At least eight die, 18 missing after ferry capsizes off North Cyprus
- Manhunt underway after woman killed, several injured at Swiss rave shooting
- Aon close to acquiring USI Insurance from KKR in $17 billion deal, WSJ reports
- RedHill sells Talicia to Apotex for $18M upfront plus milestones
BTIG Reiterates Buy Rating on Anaptysbio (ANAB) (correction)
September 5, 2024 5:14 AM EDT(Updated - September 5, 2024 5:15 AM EDT)
BTIG analyst Jake Fuller reiterated a Buy rating and $55.00 price target on Anaptysbio (NASDAQ: ANAB).
The analyst comments "We hosted a well-attended group investor meeting last week with ANAB's CEO Daniel Faga and CMO Dr. Paul Lizzul. The conversation reinforced our enthusiasm for checkpoint agonists in I&I, and we expect interest in ANAB's pipeline to continue to grow through upcoming catalysts, following a PIPE financing last month with notable... More
